The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
The advent of functional genomics has been greatly broadening our view and accelerating our way in numerous medical research fields. The complete genomic data acquired from the human genome project and the desperate clinical need of comprehensive analytical tools to study complex diseases, has allowed rapid evolution of genomic and proteomic technologies, speeding the rate and number of discoveries in new biomarkers. By jointly using genomics, proteomics and bioinformatics there is a great potential to make considerable contribution to biomarker identification and to revolutionize both the development of new therapies and drug development process.
Ferrer-Alcón
Marcel
M
Progenika Biopharma, S.A., Zamudio Technology Park, 48160 Derio, Vizcaya, Spain. mferrer@progenika.com
Arteta
David
D
Guerrero
M José
MJ
Fernandez-Orth
Dietmar
D
Simón
Laureano
L
Martinez
Antonio
A
D015415:Biomarkers; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods*; D004358:Drug Therapy; D020869:Gene Expression Profiling; D023281:Genomics; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D040901:Proteomics
D015415:Biomarkers